THERAPEUTIC APPLICATIONS OF PERFLUOROCARBON MICROBUBBLES

全氟碳微泡的治疗应用

• 批准号: 2717915
• 负责人: PATRICK L IVERSEN
• 金额: $ 9.88万
• 依托单位: AVI BIOPHARMA, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 1999-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2717915
• 关键词: albumins; antisense nucleic acid; coronary occlusion /thrombosis; fluosol; gene therapy; glucose; hyperplasia; laboratory rat; nonhuman therapy evaluation; oligonucleotides; protooncogene; swine; ultrasound therapy

DESCRIPTION (Adapted from Applicant's Abstract): Transcutaneous ultrasound-mediated destruction (UMD) of microbubbles could potentially be utilized in cardiovascular therapy. The central hypothesis of this project is that UMD of microbubbles can noninvasively (1) target delivery of antisense oligonucleotides, and (2) produce arterial thrombus microfragmentation. Since perfluorocarbon containing dextrose albumin microbubbles (PCMB) have the ability to bind antisense oligonucleotides, UMD of intravenously injected synthetic antisense oliogonucleotides bound to PCMB will be utilized to target their disposition to the myocardium and vascular wall. Subsequent to this, the applicants proposed to examine the potential for intravenous antisense to the protooncogene c-myc bound to PCMB to inhibit neointimal hyperplasia following balloon injury in an animal model. Secondly, the potential for UMD of intravenous PCMB to fragment acute coronary and carotid artery thrombi in the absence of a thrombolytic agent in an animal model will be tested. This three year project will therefore test the ability of UMD of PCMB to non-invasively (a) target gene delivery to the vascular wall, and (b) recanalize coronary and carotid thrombotic occlusions without thrombolytic therapy. Phase III studies will then test the effectiveness of antisense delivery in preventing restenosis following percutaneous revascularization procedures in humans and to improve reperfusion success rates in acute myocardial infarction. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（改编自申请人的摘要）：经皮 超声介导的微泡破坏（UMD）可能是 用于心血管疗法。 中心假设 项目是，微泡可能会无创（1）目标输送 反义寡核苷酸，（2）产生动脉血栓 微碎片。 由于含有葡萄糖白蛋白的全氟碳 微泡（PCMB）具有结合反义寡核苷酸的能力， 静脉注射的合成反义oliogon核苷酸结合的UMD 将PCMB用于针对其对心肌的处理 血管壁。 此后，申请人提议检查 与原子量c-myc结合的静脉内反义的潜力 PCMB抑制气球受伤后的新内膜增生 动物模型。 其次，静脉内PCMB的UMD可能 碎片急性冠状动脉和颈动脉血栓不存在 将测试动物模型中的溶栓剂。 这三年 因此，项目将测试PCMB UMD的能力 （a）靶基因递送到血管壁，（b）重新加入冠状动脉 没有溶栓疗法的颈动脉血栓性闭塞。 第三阶段 然后，研究将测试反义递送的有效性 预防经皮血运重建程序后再狭窄 在人类中，并提高急性心肌的再灌注成功率 梗塞。 拟议的商业应用程序：不可用